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ABSTRACT
Background: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive 
sarcoma with few treatment options. Tumor immune state has not been characterized in 
MPNST, and is important in determining response to immune checkpoint blockade. Our 
aim was to evaluate the expression of programmed death-ligand 1 (PD-L1), programmed 
cell death protein 1 (PD-1), and presence of CD8+ tumor infiltrating lymphocytes (TILs) 
in MPNST, and correlate these findings with clinical behavior and outcome.
Results: PD-L1 staining of at least 1% was seen in 0/20 nerves, 2/68 benign 
lesions and 9/53 MPNST. Two of 68 benign lesions and 7/53 (13%) MPNST had at 
least 5% PD-L1 staining. CD8 staining of at least 5% was seen in 1/20 (5%) nerves, 
45/68 (66%) benign lesions and 30/53 (57%) MPNST. PD-L1 was statistically more 
prevalent in MPNST than both nerves and benign lesions (p=0.049 and p=0.008, 
respectively). Expression of PD-1 was absent in all tissue specimens. There was no 
correlation of PD-L1 or CD8 expression with disease state (primary versus metastatic) 
or patient survival.
Methods: A comprehensive PNST tissue microarray was created from 141 surgical 
specimens including primary, recurrent, and metastatic MPNST (n=53), neurofibromas 
(n=57), schwannoma (n=11), and normal nerve (n=20). Cores were stained in 
triplicate for PD-L1, PD-1, and CD8, and expression compared between tumor types. 
These data were then examined for survival correlates in 35 patients with primary 
MPNST.
Conclusions: MPNST is characterized by low PD-L1 and absent PD-1 expression 
with significant CD8+ TIL presence. MPNST immune microenvironment does not 
correlate with patient outcome.
INTRODUCTION
Malignant peripheral nerve sheath tumor (MPNST) 
is a soft tissue sarcoma that arises from neurofibromas, 
particularly plexiform neurofibromas, or in association 
with a large nerve without an identifiable neurofibroma 
component. MPNST arise spontaneously, or can occur 
in association with neurofibromatosis type 1 (NF-1), a 
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disease characterized by the loss of the neurofibromin 
tumor suppressor protein. Patients with NF-1 have a 
10% lifetime risk of developing MPNST. MPNST often 
present as an enlarging, painful mass, and are further 
characterized on imaging with either CT or MRI. In the 
case of NF1-associated MPNST, discerning malignancy 
from benign neurofibromas is a clinical challenge that has 
led to the utilization of PET imaging in tumor diagnosis 
[1].
MPNST are best managed by multidisciplinary 
teams at tertiary sarcoma referral centers [2]. Surgery is 
the foundation of therapy for MPNST, however a major 
unmet clinical need is in patients who are poor surgical 
candidates or have relapsed/systemic disease. MPNST 
remain chemo-resistant, and long term outcomes are 
poor. Recent developments in molecular biology have 
uncovered alterations in several important growth 
and developmental pathways in this disease including 
the Ras-MAPK pathway, the Wnt-Beta-Catenin 
pathway, the mTOR pathway, and in PTEN and p53 
[3]. However, targeted therapies to date have not been 
very efficacious; as such new therapeutic modalities are 
needed.
Immune-based therapies have shown significant 
therapeutic efficacy in numerous tumor types, including 
advanced melanomas and non-small cell lung cancers.[4–
7] Immune-induced tumor programmed cell death-ligand 
1 (PD-L1) expression is considered to be an adaptive 
immune resistance mechanism for tumor cells in response 
to immune challenge.[8–10] Sufficient T cell infiltration is 
essential for response to PD-L1 blockade. The presence of 
tumor escape or suppression of tumoral immune response 
has not been well studied in patients with sarcoma. In this 
study, we characterized the expression of programmed cell 
death protein 1 (PD-1), PDL-1 and CD8 tumor infiltrates 
in MPNST, neurofibromas, schwannomas, and in normal 
nerve tissue, and correlated these factors with patient 
outcome.
RESULTS
Patient characteristics
Of the patients with MPNST (n=53), 33 (62.3%) 
were spontaneous tumors and 20 (37.7%) were NF-1 
associated MPNST. Most patients had primary (71.7%, 
n=38), high grade (83.0%, n=44), large tumors (mean 
11.9 cm, median 10 cm, range 1-45cm) located on 
the extremity (43.4%, n=23). (Table 1) The majority 
of MPNST patients in this study were not treated 
with neoadjuvant chemotherapy (58.5%, n=31) or 
neoadjuvant radiation therapy (69.8%, n=37) before the 
surgical specimen was retrieved. Median follow-up time 
for MPNST survivors was 6.1 years (range 2.3-15.8 
years). The primary site of metastatic disease, when it 
occurred in this MPNST patient cohort, was the lung.
PD-L1 expression is significantly higher in 
MPNST when compared to benign tumors
To examine the immune microenvironment of 
benign and malignant tissues, we quantified PD-L1 
expression and CD8 positivity in a wide array of patient 
samples using 1% and 5% positive threshold criteria. 
We found no difference in expression of PD-L1 in 
normal nerve as compared to benign neurofibromas and 
schwannomas (p=0.438). CD8+ immune infiltrates, 
however, were significantly elevated in benign peripheral 
nerve sheath tumor (45/68 benign PNST) as compared to 
normal nerve (6/20 nerves) using a 1% threshold, p=0.004. 
In the comparison of normal nerves to MPNST, malignant 
tumor samples exhibited significantly higher PD-L1 
expression (9/53 MPNST samples versus 0/20 nerve 
samples; p=0.049, Figure 1). CD8 immune infiltrates were 
present in a significantly higher proportion in MPNST 
tumors (30 of 53 samples) as compared to normal nerve 
(6 of 20 samples, p=0.043, see Figure 2). PD-1 showed no 
staining in any tissue specimens (Figure 3).
Using a more stringent 5% threshold for positivity, 
MPNST tumors had a significantly higher prevalence of 
PD-L1 expression than benign peripheral nerve sheath 
tumors (2 of 68 benign PNST; 7 of 53 MPNST; p=0.033). 
There was no difference in the presence of CD8+ immune 
infiltrates between benign PNST and MPSNT using a 5% 
threshold (p=0.282, see Figure 2).
Comparison of the tumor immune 
microenvironment in localized and metastatic 
MPNST
To characterize the tumor immune microenvironment 
as a MPNST progresses from primary to metastatic tumor, 
we examined PD-L1 expression and the presence of 
CD8 immune infiltrates in 38 primary MPNST samples, 
10 recurrent MPNST samples, and 5 metastatic MPNST 
samples. There was no significant difference in PD-L1 
expression between primary (18%), recurrent (20%), 
or metastatic (0%) samples (Table 2). When examining 
the presence of CD8 immune infiltrates, there was no 
significant difference between primary (53%), recurrent 
(80%), and metastatic samples (40%) (Table 2).
PD-L1 expression and CD8 TIL co-presence
Given that PD-L1 is inducible and may reflect 
homeostatic responses to immune activation [6], 
characterizing the immune infiltrate is important in 
contextualizing tumoral PD-L1 expression. Both CD4 
and CD8 cell expression have prognostic implications 
in soft tissue sarcoma.[11, 12] Therefore, we examined 
the synchronous presence of PD-L1 expression and CD8 
TILs in all neurogenic tissues. Of the samples with both 
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strong PD-L1 and CD8 expression, 100% were in patients 
with malignant tumors. Of these nine patients, four 
were in primary MPNST samples, two were in MPNST 
recurrent tumors, two were from primary MPNST tumors 
in patients with concomitant metastases, and one was in a 
neurofibroma sample adjacent to a primary MPNST.
Significance of PD-L1 expression and CD8 
positivity on MPNST patient survival
We explored patient disease specific survival (DSS) 
and disease free survival (DFS) in relation to PD-L1 and 
CD8 levels. Thirty-eight patients with primary MPNST 
Table 1: Patient Characteristics
MPNST Patient Characteristics
n %
Total MPNST patients 53 100
Genetic Background
Spontaneous 33 62.3
NF-1 associated 20 37.7
Tumor Type
Primary 38 71.7
Recurrent 10 18.9
Metastatic 5 9.4
Grade
High 44 83.0
Intermediate 8 15.1
Low 1 1.9
Location
Extremity 23 43.4
Pelvic/Retroperitoneal 16 30.2
Trunk 7 13.2
Head and Neck 5 9.4
Other 2 3.8
Neoadjuvant Chemotherapy
Yes 22 41.5
No 31 58.5
Neoadjuvant Radiation
Yes 16 30.2
No 37 69.8
Tumor Size
Mean 11.9cm
Median 10cm
Range 1-45cm
Follow up
Mean 6.1 years
Range 2.3-15.8 years
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Figure 1: PD-L1 Expression. 1-5 cores from different blocks were stained for PD-L1, PD-1 and CD8+ and scored based on intensity 
of staining on a scale of 0-3 and percent of cells staining positively. Significance of staining differences between groups was compared via 
chi squared analysis and survival analysis was performed using a Cox proportional hazards model. PD-L1 staining of at least 1% was seen 
in 0/20 nerves, 2/68 benign lesions and 9/53 malignant lesions. PD-L1 staining of at least 5% was seen in 0/20 nerves, 2/68 benign lesions 
and 7/53 malignant lesions. PD-L1 was statistically more prevalent in MPNST than both nerves and benign lesions (p=0.049 and p=0.008, 
respectively) at the 1% level, but only benign lesions at the 5% level (p=0.033).
Figure 2: CD8+ infiltrate. CD8+ of at least 1% was seen in 6/20 (30.0%) nerves, 45/68 (66.2%) benign lesions and 30/53 (56.6%) of 
MPNST. CD8+ of at least 5% was seen in 1/20 (5.0%) nerves, 14/68 (20.6%) benign lesions and 11/53 (20.7%) of MPNST. There was no 
difference between benign and malignant tumors at the 5% (p=0.282) or 1% (p=0.982) expression threshold.
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tumors were included in the tissue microarray. Three of 
the samples came from the primary tumor of patients 
who also had concurrent metastases, and were therefore 
excluded from the analysis. Median DSS was 24 months 
(range 3 months - 15 years). Of the 35 remaining patients 
with primary MPNST, DSS analysis revealed no survival 
correlates to PD-L1 or CD8 expression (PD-L1 5% 
criteria: NS, p=0.717; PD-L1 1% criteria: NS, p=0.342; 
CD8 5% criteria: NS, p=0.459; CD8 1% criteria: NS, 
p=0.938).
Analysis of DFS was limited to 33 patients, as two 
patients with primary non-metastatic MPNST had DFS 
less than one month from surgery and were censored from 
the analysis. Of the 33 patients with primary MPNST who 
underwent R0 surgical resection, DFS did not correlate 
with PD-L1 nor CD8 expression (PDL1 5% criteria: NS, 
p=1; PDL1 1% criteria: NS, p=0.630, CD8 5% criteria: 
NS, p=0.553; CD8 1% criteria: NS, p=0.109).
DISCUSSION
The immune system has the capacity to recognize 
and eliminate cancer cells, but can be restrained by 
inhibitory mechanisms in the tumor environment. To 
date the immunosuppressive effects of the MPNST 
tumor microenvironment are still largely unknown [13]. 
Figure 3: Representative immunohistochemical stainings of PD-L1, PD-1, and CD8+ for nerve, benign peripheral 
nerve sheath tumors, and malignant peripheral nerve sheath tumors.
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Immune checkpoint pathways maintain self-tolerance and 
limit damage to host tissues during an immune response, 
but these pathways can be exploited by cancer cells to 
evade immune destruction [10]. Monoclonal antibodies 
interrupting immune checkpoints, such as anti-CTLA-4, 
anti-PD-1, and anti-PD-L1 can unleash anti-tumor 
immunity and mediate durable cancer regressions. While 
the presence of PD-L1 expression is considered the best 
available biomarker for PD-L1/PD-1 blockade, several 
other predictive biomarkers of response to checkpoint 
blockade are currently being explored.[14–17].
Programmed-death (PD) pathway blockade has 
resulted in significant and durable clinical responses in 
patients with a broad spectrum of so-called “inflamed 
cancers”—such as melanoma, renal cell carcinoma, lung 
cancer, mismatch repair-deficient colorectal cancer, and 
bladder cancer—characterized by a high prevalence of 
neo-antigens, elevated PD-L1 expression, and robust 
infiltration of cytotoxic T cells (see review of “inflamed 
cancer” by Zou et al.) [18]. On the other hand, “non-
inflamed” cancers with poor T cell trafficking and low 
PD pathway activity are thought to be less susceptible to 
single-agent PD pathway immunotherapy and may require 
combinatorial regimens in order to induce a clinically-
meaningful response. Characterizing the immunologic 
microenvironment of malignant peripheral nerve sheath 
tumors (MPNST) as “inflamed” or “non-inflamed” is 
therefore important because it may lend insight into 
whether patients with advanced MPNST respond to 
single-agent PD pathway blockade or may indicate 
when alternative immunotherapeutic approaches such as 
adoptive transfer of T cells or combination immunotherapy 
may be more appropriate.
The principal aim of this study was to characterize 
the immunologic microenvironment of MPNST by 
quantifying infiltration of cytotoxic CD8+ T cells and 
measuring the expression of programmed death-1 (PD1) 
and programmed-death-1 ligand-1 (PD-L1). Given that 
the immunologic microenvironment has prognostic 
significance in a variety of cancer histologies, we also 
sought to clarify whether cytotoxic T cell infiltration and 
PD1/PD-L1 expression correlated with disease progression 
and patient survival.
To evaluate PD pathway activity in MPNST, we 
used one of the largest prospective datasets of MPNST 
available which includes tumor specimens from 86 
patients collected between 1982 and 2009 at a single 
institution. We found significant (57%) infiltration of 
cytotoxic T cells in the MPNST microenvironment but 
an absence of PD1 expression and low levels of PD-L1. 
The CD8+ T cell infiltration was essentially limited to 
MPNST with minimal infiltration in normal nerve and 
benign tumor (p=0.043). We also observed that only 9 out 
of 53 MPNST tumor specimens had expression of PD-L1, 
and only at relatively low levels (less than 1% of cells 
per high-power field). Furthermore, we found that disease-
specific survival and disease-free survival among patients 
in our study were not associated with expression of PD-L1 
or the presence of tumor-infiltrating CD8+ lymphocytes.
Previous studies evaluating the activity of the PD 
pathway in patients with MPNST and other sarcomas for 
that matter are limited by their small sample sizes and have 
produced mixed results. In a case series of 105 patients 
with various soft tissue sarcomas, Kim et al. found that 3 
out of 6 patients with MPNST showed expression of both 
PD1 and PD-L1 in the tumor microenvironment [19]. In 
another case series of 50 patients with a variety of soft 
tissue sarcomas, one patient with MPNST was found to 
have an absence of PD-L1 expression on both tumor and 
lymphocytes [20].
It has been suggested that non-inflamed tumor types 
have prominent features of epithelial to mesenchymal 
transition and stem-like characteristics with a paucity of 
neo-antigens and multiple layers of immunosuppressive 
mechanisms. Of the 53 patients with MPNST in the 
present study, 44 (83%) had high-grade disease consistent 
with a non-inflamed phenotype. The emerging complexity 
of immunoregulatory mechanisms in non-inflamed cancers 
might limit the efficacy of single-agent PD pathway 
blockade and suggest that the most effective treatment 
for patients with MPNST may involve a combinatorial 
approach including enforcing T cell trafficking with 
Table 2: Expression of CD8+ and PD-L1 in primary, recurrent, and metastatic MPNST
Primary MPNST Recurrent MPNST Metastatic MPNST
PD-L1 PD-L1 (1%) = 2/10 PD-L1 (5%) = 2/10 PD-L1 (1%) = 0/5 PD-L1 (5%) = 0/5
PD-L1 (1%) = 7/38 p=0.909 p=0.294
PD-L1 (5%) = 5/38 p=0.585 p=0.388
CD8+ CD8+ (1%) = 8/10 CD8+ (5%) = 2/10 CD8+ (1%) = 2/5 CD8+ (5%) = 0/5
CD8+ (1%) = 20/38 p=0.118 p=0.595
CD8+ (5%) = 9/38 p=0.805 p=0.221
No significant differences were noted in the expression level of PD-L1 or the amount of CD8+ lymphocytes between 
primary and recurrent or metastatic MPNST samples.
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epigenetic reprogramming drugs, supplementation of 
effector T cells with adoptive transfer, and subversion of 
other immunosuppressive elements such as T regulatory 
cells in the tumor microenvironment.
Current cytotoxic treatments of MPNST, such 
as adriamycin and ifosfamide, lack efficacy,[21] and 
the rarity of these tumors is a barrier to appropriately 
powered randomized controlled studies testing novel 
chemo- and immunotherapeutics [22]. To maximize 
the value of information derived from relatively small 
numbers of human tumors, the use of murine models 
may lend insight into MPNST pathogenesis and potential 
treatments. Murine models of MPNST are of important 
use for basic and translational research as they can mimic 
the clinical pattern of growth and metastasis.[23–25] 
Cross-species comparative oncogenomics may help to 
identify functionally validated molecular drivers for 
study in human MPNST, and patient-derived orthotopic 
xenografts may provide a platform for future testing of 
novel therapeutics.[26, 27] Thus, a potential area of further 
study is the examination of targeted chemotherapy and 
combinatorial PD pathway blockade in transgenic and 
patient-derived orthotopic xenograft MPNST models.
In conclusion, we assembled a large cohort of 
patients with MPNST to provide a broad view of the 
immunologic landscape of primary and metastatic 
tumors. The finding that MPNST tumors resemble “non-
inflamed” cancers in terms of low PD activity and T cell 
infiltration has major therapeutic implications for how PD 
blockade may be supplemented with other immunotherapy 
modalities to develop a combinatorial approach to promote 
durable and potent anti-tumor immunity.
MATERIALS AND METHODS
Patients
The University of California – Los Angeles (UCLA) 
Comprehensive Cancer Center is one of the highest volume 
sarcoma programs in the nation. The Sarcoma Program 
at UCLA provides innovative multidisciplinary treatment 
for patients with sarcoma in all stages of disease. Since 
1974, Sarcoma Program at the University of California 
– Los Angeles (UCLA) Comprehensive Cancer Center 
has prospectively maintained a peripheral nerve sheath 
tumor database with clinical and pathologic patient data. 
A protocol detailing the study design and analysis was 
approved by the UCLA Institutional Review Board (IRB) 
and the Jonsson Comprehensive Cancer Center. For 
inclusion, subjects were required to have tissue diagnosis 
of a peripheral nerve sheath tumor, undergone surgery and 
treatment of the tumor at UCLA, and have documented 
follow-up after surgery. 267 unique patients were eligible 
for study, of those 86 patients comprising 141 surgical 
specimens had tissue available for inclusion in the tissue 
microarray: 53 MPNST specimens, 57 neurofibromas, 11 
schwannomas, and 20 normal nerve samples from a period 
of 27 years (1982-2009). When available, specimens 
of normal nerve and neurofibroma were sampled from 
MPNST resection specimens; additionally if a patient 
later underwent surgical resection of recurrent and/or 
metastatic MPNST, these tumors were also included in the 
microarray. Original surgical specimens were reviewed by a 
UCLA sarcoma pathologist (S.M.D.) to confirm pathologic 
diagnosis and grading. All medical records were reviewed to 
confirm accuracy of the prospectively maintained database.
Tissue microarray and specimen characteristics
As part of the translational component of study #10-
001857 approved by the UCLA IRB, a tissue microarray 
was created from 141 surgical specimens (NF-1 associated 
MPNST n=20, spontaneous MPNST n=33, neurofibroma 
n=57, schwannoma n=11, and normal nerve n=20) over a 
period of 27 years (1982-2009) from a single institution. 
Of the 53 MPNST samples, 38 were primary tumors, 10 
were recurrent tumors, and 5 were metastatic (Table 1). 
Tissue was formalin-fixed and paraffin-embedded, and 
cores were selected by a sarcoma-specific pathologist 
(S.M.D.) and compiled in the tissue microarray. If 
possible, multiple cores were selected from a single tumor 
to account for tumor heterogeneity.
Immunohistochemistry
Given that PD-L1 is inducible and may reflect 
homeostatic responses to immune activation, we 
contextualized our evaluation of PD-L1 with the 
synchronous presence CD8+ TILs in all neurogenic tissues. 
Cores were stained in triplicate for PDL-1, PD-1, and CD8+ 
TIL. Sections were deparaffinized in xylene and rehydrated 
in graded alcohol. Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide (H2O2). Antigen 
retrieval was performed by boiling the sections in 0.01M 
citric acid buffer (pH 6.0) for 15 min. Sections were first 
blocked with anti CD8 antibody (DAKO, M7103) at a 1:50 
dilution for one hour, then incubated with Dako EnVision+ 
System –HRP Labelled Polymer Anti-Mouse (Dako, 
K4001) at room temperature for 30 minutes, incubated 
with DAB (3, 3'-Diaminobenzidine) for visualization, and 
then counterstained with Gill’s hematoxylin, dehydrated 
in ethanol, and mounted with media. For PD-L1 and PD-
1, sections were incubated in 5% normal donkey serum, 
and then incubated overnight at 4°C with primary antibody 
against PD-L1 (Spring Bioscience, Cat: M4420, 1:200) 
and PD-1 (Cell Marque, Cat:315M-96, 1:100). Sections 
were then incubated with Dako EnVision+ System –
HRP Labelled Polymer Anti-Rabbit (Dako, K4003) or 
Anti-Mouse (Dako, K3001) at room temperature for 30 
minutes, incubated with DAB (3, 3'-Diaminobenzidine) 
for visualization, and then counterstained with Gill’s 
hematoxylin, dehydrated in ethanol, and mounted with 
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media. Sections were counterstained in Gill’s hematoxylin. 
Negative and positive control slides were included. Digital 
images of sections were obtained using a ScanScope 
XT System (Aperio Technologies Inc, Vista, CA) at 
400X magnification courtesy of the UCLA Translational 
Pathology Core Laboratory. Protein expression scores 
were defined as the percentage of positively stained tumor 
cells relative to total tumor cells within the section, and 
were reviewed by a sarcoma-specific pathologist (S.M.D.). 
Density (number of cells stained/HPF) and intensity (grade 
of pigment saturation) were quantified on a scale of 0 to 
3. Two criteria for staining “positivity” were utilized in 
parallel: “5% criteria” defined a specimen as positive if 
staining intensity was graded 2 or 3 with greater than or 
equal to 5% positive cells in any of the cores; “1% criteria” 
defined a specimen as positive if staining intensity was 
graded 2 or 3 with greater than or equal to 1% positive 
cells in any of the cores. Assays and staining quantification 
were performed blinded to the study endpoints.
Study design
Case selection was determined prospectively, and 
was diversified to include malignant and benign peripheral 
nerve sheath tumors. The primary survival endpoint was 
disease specific survival of MPNST patients, defined 
as time from surgery to death due to disease, and the 
secondary survival endpoint was disease free survival, 
defined as time from surgery to time of tumor recurrence.
Statistical analysis methods
Multiple cores from a single tumor were 
analyzed with staining scores 0-3. Low tumor scores 
were designated as <1, and high staining scores ≥1. 
Biomarker staining was compared using a Pearson Chi 
squared analysis (alpha ≤ 0.05) and survival analysis 
was performed using a Cox proportional hazards model 
with testing of the proportional hazards assumption. 
In the survival analysis, patients lost to follow up were 
censored at their last UCLA follow-up date. Only patients 
with primary MPNST who underwent R0 resection were 
included in the survival analysis, as survival significantly 
decreases with microscopic/macroscopically positive 
margins in patients with soft tissue sarcoma [28]. 
Analysis of the datasets was performed using STATA 12.0 
(StataCorp., 2011).
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